tbuckley/cabot-search huggingface dataset:
American Journal of Pathology, New York
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
JAMA Reference Directories
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1717: Variants of uncertain significance of the cancer predisposing genes in 3.5 thousand Japanese whole genome sequencing data
Authors: Jun Yasuda
Journal: Cancer Research (2019)

Abstract Many of the cancer predisposing genes are known to be associated with juvenile cancer syndromes such as Li Fraumeni syndrome. The responsible variants of the juvenile cancer syndromes are usually very deleterious and show strong biological effects on the gene functions. It is not so easy to estimate the clinical significance of the moderately deleterious variants in those genes that may have clinically significant effects on the hosts’ cancer predisposition and these moderately deleterious (or hypomorphic) variants are now classified as variants of uncertain significance (VUSs). The insight that VUSs may have moderate but clinically significant effects on cancer susceptibility now attracts cancer geneticists. To elucidate the state of VUSs of more than 150 cancer predisposing genes in general population, we functionally annotate the single nucleotide variants (SNVs) in the genes from a 3,552 whole genome sequence dataset (3.5KJPN) obtained from participants in a genome cohort by Tohoku Medical Megabank Organization. Frequency spectrum of the Combined Annotation-Dependent Depletion (CADD) and deleterious annotation of genetic variants using neural networks (DANN) scores of the more than 150 cancer predisposing genes will be discussed. Finally, the association of the CADD and DANN scores with the past and family histories will be analyzed. Citation Format: Jun Yasuda. Variants of uncertain significance of the cancer predisposing genes in 3.5 thousand Japanese whole genome sequencing data [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1717.
A phase II study of pemetrexed combined with cisplatin in patients (pts) with recurrent or metastatic nasopharyngeal carcinoma.
Authors: A. W. M. Lee, T. K. Yau, T. C. Shum, W. T. Ng, L. L. Chan, R. M. Yeung
Journal: Journal of Clinical Oncology (2011)

5538 Background: Nasopharyngeal carcinoma (NPC) is a chemo-sensitive disease but there is yet no consensus on the best regimen for recurrent or metastatic diseases. Pemetrexed is a new agent with good efficacy and toxicity profiles in other cancers. This phase II study aims to evaluate its use in combination with cisplatin for NPC. Methods: Patients (pts) with metastatic or extensive recurrence (unsuitable for radical surgery or re-irradiation) were included. All had prior treatment with platinum-based chemotherapy. The regimen consisted of pemetrexed 500mg/m2 (with vitamin B12 and folic acid support) and cisplatin 75mg/m2 every 3 weeks. Assessments of efficacy were based on both radiological and biochemical (DNA copies of Epstein-Barr virus) response. Toxicity profile was assessed by both acute toxicity rates and quality of life (QOL) scores (measured with FACT-H&N version 4). Patients with response/stable disease and good tolerance were given another 2-4 cycles. Results: Fourteen pts (5 with loco-regional recurrences and 9 with metastases) were treated with this regimen; their median age was 51 (range, 39-68) years. All except one pts had elevated EBV-DNA (median, 34,750 copies/ml; range, 42–17,500,000). A total of 4-8 (median, 6) cycles had been given. Reduction of EBV-DNA copies by >=50% was observed in 12/13 (92%) pts, 2/13 (15%) pts even achieved biochemical complete remission (CR). Radiological assessment showed that one (7%) pt achieved CR, 2 (14%) had partial remission and 7 (50%) had stable diseases. The median time to progression was 30 weeks (range, 11-119 weeks). Only one pt (7%) developed grade 4 toxicity (anemia). The most common grade 3 toxicities were neutropenia (29%) and anemia (21%). All 14 pts had QOL assessment at baseline and after the fourth cycle; 12 (86%) pts had further assessment after the sixth cycle. No significant deterioration in QOL was observed: the total QOL scores (mean) changed from 99 at baseline to 95 after the fourth cycle (p=0.35) and 90 after the sixth cycle (p=0.16). Conclusions: Cisplatin-pemetrexed was a well tolerated regimen and the efficacy for metastatic/recurrent NPC was encouraging. Further evaluation of its role in treatment of NPC is warranted.
Initial medical assessment of Kurdish refugees in the Turkey-Iraq border region
Authors: R. H. Sandler
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Smoking and lung function in elderly men and women. The Cardiovascular Health Study
Authors: M. W. Higgins
Journal: JAMA (1993)

<h3>Objective.</h3> —To investigate relationships between cigarette smoking and pulmonary function in elderly men and women. <h3>Design.</h3> —Cross-sectional analysis of baseline data from a prospective, population-based study of risk factors, preclinical, and overt cardiovascular and pulmonary disease. <h3>Setting.</h3> —Defined communities in Forsyth County, North Carolina; Pittsburgh, Pa; Sacramento County, California; and Washington County, Maryland. <h3>Population.</h3> —A total of 5201 noninstitutionalized men and women 65 years of age and older. <h3>Main Outcome Measures.</h3> —Pulmonary function; means of forced expiratory volume in 1 second (FEV<sub>1</sub>) and forced vital capacity and prevalence of low FEV<sub>1</sub>levels. <h3>Results.</h3> —Prevalence of cigarette smoking was 10% to 20% and higher in women than men and in blacks than whites. Forced vital capacity and FEV<sub>1</sub>levels were related positively to height and white race and negatively to age and waist girth. Age- and height-adjusted FEV<sub>1</sub>means were 23% and 18% lower in male and female current smokers, respectively, than in never smokers but not reduced in never smokers currently living with a smoker. Smokers who quit before age 40 years had FEV<sub>1</sub>levels similar to never smokers, but FEV<sub>1</sub>levels were lower by 7% and 14% in smokers who quit at ages 40 to 60 years and older than 60 years, respectively. Lung function was related inversely to pack-years of cigarette use. Prevalence rates of impaired lung function were highest in current smokers and lowest in never smokers. Regression coefficients for the smoking variables were smaller in persons without cardiovascular or respiratory conditions than in the total cohort. <h3>Conclusions.</h3> —Cigarette smoking is associated with reduced pulmonary function in elderly men and women. However, smokers who quit, even after age 60 years, have better pulmonary function than continuing smokers. (<i>JAMA</i>. 1993;269:2741-2748)
What's new in the other general journals
Authors: Alison Tonks
Journal: BMJ (2006)

Randomised trials are rarely big enough, long enough, or powerful enough to give patients the information they want about rare but serious side effects. In an unusual move, researchers used meta-analysis, a powerful tool for combining trial results, to find out more about the cancer causing potential of a treatment for rheumatoid arthritis—the monoclonal antibodies infliximab and adalimumab. Both are directed against tumour necrosis factor. Credit: JAMA Pooled data from nine placebo controlled trials, which included more than 5000 patients, showed that the antibodies were associated with a significantly greater risk of cancer (odds ratio 3.3, 95% CI 1.2 to 9.1) and of serious infections (2.0, 1.3 to 3.1). Overall, 24 of the 3493 patients given monoclonal antibodies developed cancer (0.8%), compared with three of the 1512 given placebo (0.2%). Higher doses were associated with higher risk of cancer. These findings are consistent with what we already know about tumour necrosis factor—it helps combat infections and kills tumour cells—and with what researchers suspected might happen when it was disabled. The results are also consistent with previous hints from postmarketing surveillance, cohort studies, and individual trials. The authors say they are among the first to use meta-analysis to assess a drug's safety, and it works well. They suggest others follow suit. JAMA2006;295: 2275–85 [OpenUrl][1][CrossRef][2][PubMed][3][Web of Science][4] Fifty years after someone first noticed the connection between air travel and venous thrombosis, scientists are still trying to untangle the complex relationship between haemostasis, sitting still for a long time, and the combined effects of low pressure and low oxygen tension in the cabin. In the latest controlled experiment, hypobaric and hypoxic conditions mimicking a long haul flight did not alter volunteers' haemostasis any more than sitting for eight hours in conditions mimicking a deck chair in the garden at 50-70 m above sea level. Serum markers for coagulation, … [1]: {openurl}?query=rft.jtitle%253DJAMA%26rft.stitle%253DJAMA%26rft.issn%253D0002-9955%26rft.aulast%253DBongartz%26rft.auinit1%253DT.%26rft.volume%253D295%26rft.issue%253D19%26rft.spage%253D2275%26rft.epage%253D2285%26rft.atitle%253DAnti-TNF%2Bantibody%2Btherapy%2Bin%2Brheumatoid%2Barthritis%2Band%2Bthe%2Brisk%2Bof%2Bserious%2Binfections%2Band%2Bmalignancies%253A%2Bsystematic%2Breview%2Band%2Bmeta-analysis%2Bof%2Brare%2Bharmful%2Beffects%2Bin%2Brandomized%2Bcontrolled%2Btrials.%26rft_id%253Dinfo%253Adoi%252F10.1001%252Fjama.295.19.2275%26rft_id%253Dinfo%253Apmid%252F16705109%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/external-ref?access_num=10.1001/jama.295.19.2275&link_type=DOI [3]: /lookup/external-ref?access_num=16705109&link_type=MED&atom=%2Fbmj%2F332%2F7552%2F1264.atom [4]: /lookup/external-ref?access_num=000237556600026&link_type=ISI
Health Care Delivery
Journal: Hepatology (2013)

Purpose: Nationally, 50% of HCV antibody positive individuals may never receive a confirmatory test.Low rates of confirmatory testing are attributed to patient, provider and health system barriers.These barriers are compounded in medically underserved communities with high rates of HCV infection.Methods: We developed a comprehensive neighborhood-based HCV testing and linkage to care program in Southwest Philadelphia.HCV screening was performed on a mobile testing unit using the Oraquick rapid HCV antibody test.All individuals with reactive rapid tests received reflexive confirmatory testing on the mobile unit with an HCV PCR quantitative assay via blood draw.Laboratory specimens were processed at a nearby hospital laboratory and centrifuged within 6 hours of blood draw.Antibody positive clients received risk reduction counseling and were provided with confirmatory test results.Chronically infected patients with no medical insurance were provided case management.Linkage to medical care was supported by a case management team that also accompanied patients to their first two appointments with a subspecialist.Results: The Do One Thing Campaign tested 486 individuals in a community based, non-clinical setting from Dec 20, 2012 to May 14, 2013.Anti-HCV seroprevalence was 4%.All patients have received confirmatory testing and 96% of patients received their confirmatory test results.Eighty percent of the anti-HCV positive clients were chronically infected.Of those with chronic infection, 4 were uninsured and received case management for insurance applications.Nine clients have been seen by a subspecialty provider to evaluate their HCV.All other chronically infected patients are either currently engaged in the process of obtaining insurance, awaiting a referral from a primary care provider or have home visits scheduled with our linkage to care outreach team.Conclusion: This non-clinical HCV testing model enables individuals who may not have otherwise accessed medical care to learn their HCV status and to access HCV care and treatment.Offering immediate confirmatory testing for HCV antibody positive individuals eliminates the need for a return visit to a health care provider.A model that combines rapid HCV testing, reflexive confirmatory testing, risk reduction counseling, and aggressive case management can further reduce barriers to HCV treatment and care.Our model could be used to enhance HCV testing and treatment in other heavily impacted communities with limited access to medical care.
Delaying the diagnosis of disease
Authors: Ira A. Shulman, Janice M. Nelson, Donald R. Branch
Journal: JAMA (1985)

<h3>In Reply.—</h3> The serological features that characterize patients with combined cold- and warm-antibody autoimmune hemolytic anemia are the finding of both IgG and C3d on their red blood cells and the presence in their serum of both IgG warm autoantibodies and high-thermal-amplitude cold autohemagglutinins.<sup>1</sup>High-thermal-amplitude cold autohemagglutinins are reactive over a broad temperature range from 0 °C to 30 °C and higher. Nusbaum and Khosla report the condition of a patient whom they believe had combined cold- and warm-antibody autoimmune hemolytic anemia, similar to the patients reported by us inThe Journal. Unfortunately, their case report failed to mention important serological data necessary to substantiate their claim. Neither the results of their patient's direct antiglobulin test with anticomplement reagents nor the thermal amplitude of their patient's serum cold agglutinin were reported. Without this information, it is impossible to ascertain whether their patient had combined cold- and warm-antibody autoimmune hemolytic
THE CLUMPING OF BACILLI AND OF RED CORPUSCLES.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Metered-Dose Inhalers: Drug Delivery Over the Life of a Canister-Reply
Authors: Arthur Bergner
Journal: JAMA (1993)

<h3>In Reply.</h3> —Our letter attempted to address only the problem and potential consequences of asthmatics using MDIs beyond the number of sprays specified by the manufacturer. We limited the scope of the issue so that it could be supported by available evidence. However, many of our patients have volunteered their observations, which tend to confirm Weiss' personal experience, namely, that their sprays at times decline in force, volume, or effectiveness before the specified number has been used, even though they shake the MDI before each actuation. Decreased dose problems are not more obvious to most patients for several reasons. Gradual changes of force, volume, or active ingredients are not easily perceived when sprayed into the mouth, and especially if a spacer (extender) is used. Patients generally do not count sprays and are not aware of how close they are to the end of the specified number of sprays. Therefore, when
Book Review Practical Massage and Corrective Exercises with Aplied Anatomy . By Hartvig Nissen, late President of Posse Normal School of Gymnastics; former Director of the Swedish Health Institute. Washington, D. C., etc. Fifth Edition, Revised and Enlarged by Harry Nissen, President, Posse Nissen School of Physical Education, Boston, Mass. Illustrated with 72 Original Half-tone and Line Engravings. Philadelphia, F. A. Davis Company, Publishers, 1929. Price $2.50.
Journal: New England Journal of Medicine (1930)
STATE MEDICAL ASSOCIATIONS TO MEET ON CONTINUING EDUCATION
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SUGAR IN NORMAL URINE
Journal: JAMA (1925)

Two features of physiologic and pathologic carbohydrate metabolism seem to be commonly accepted at present. One is the conclusion that the normal circulating sugar of the blood is the carbohydrate glucose; the other is the fact that, under those conditions familiarly termed diabetic, the eliminated urinary carbohydrate is the same sugar. For a long time it has been known also that the kidney secretion in apparent health may contain small quantities of reducing substances that have the earmarks of carbohydrates. They are found so constantly that the term glycuresis has been coined to designate their genesis or elimination. Consequently, the idea has arisen that true glycosuria represents only an augmentation or exaggeration of the almost negligible but nevertheless detectable glycuresis or sugar leakage to which every kidney is subject. The contrasts between glycuresis and what has long been recognized as glycosuria would thus be merely those of quantitative differences rather
New Names
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal